From: Long-term outcomes in Ornithine Transcarbamylase deficiency: a series of 90 patients
Neonates | Group 1 m-16y | Group >16y | |
---|---|---|---|
Number of cases | 27 | 52 | 11 |
Males | 22 | 21 | 5 |
females | 5 | 31 | 6 |
Number of deceased | 20 | 7 | 1 |
at diagnosis | 13 | 5 | 1 |
during follow up | 7 | 2 | 0 |
Number of decompensations per patient (and relative to mean length of follow-up)* | 6,2 (1.0/yr) | 2,5 (1/10 yrs) | 1,4 (<1/20 yrs) |
Neurological score (IQ) at last follow up, N > 80 | 90 | 92 | Normal socio-professional insertion |
Mean peak plasma ammonia at diagnosis (μmol/L), N < 50 μmol/L | 960 | 500 | |
Mean plasma glutamine at diagnosis (μmol/L), N: 530 +/- 81 μmol/L | 4110 | 1000 | |
Plasma citrulline at diagnosis (μmol/L), N: 26+/-8 μmol/L | 5 | 15 | 14 |